| Terminated | Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome Myelodysplastic Syndrome (MDS) | Phase 2 | 2011-10-01 |
| Terminated | Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome Myelodysplastic Syndrome (MDS) | Phase 2 | 2011-10-01 |
| Completed | Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myelom Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma | Phase 2 | 2010-06-01 |
| Completed | Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 R Myelodysplastic Syndrome | Phase 1 | 2009-11-01 |
| Terminated | Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia Severe Chronic Neutropenia | Phase 2 | 2009-04-01 |
| Terminated | Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cance Non-small Cell Lung Cancer | Phase 2 | 2008-10-01 |
| Completed | Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) Myelodysplastic Syndrome (MDS) | Phase 2 | 2008-05-01 |
| Terminated | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovari Ovarian Neoplasms | Phase 3 | 2006-05-01 |
| Completed | Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) Myelodysplastic Syndrome (MDS) | Phase 1 / Phase 2 | 2006-02-01 |
| Completed | TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Neoplasms | Phase 3 | 2004-12-01 |
| Completed | Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | 2004-08-01 |
| Completed | TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer ( Non-small Cell Lung Cancer | Phase 1 / Phase 2 | 2004-02-01 |
| Completed | TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer Ovarian Neoplasms | Phase 3 | 2003-06-01 |
| Completed | TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer Ovarian Neoplasms | Phase 1 / Phase 2 | 2003-02-01 |
| Completed | TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer Ovarian Neoplasms | Phase 1 / Phase 2 | 2003-01-01 |
| Completed | Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Docetaxel in Platinum-Resistant Non-Small Cell Lun Carcinoma, Non-small-cell Lung | Phase 1 / Phase 2 | 2002-10-01 |
| Completed | Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer Carcinoma, Non-small-cell Lung | Phase 2 | 2002-07-01 |
| Completed | Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome Myelodysplastic Syndromes | Phase 1 / Phase 2 | 2002-04-01 |
| Completed | Phase 2 Study of TLK286 in Metastatic Breast Cancer Breast Neoplasms | Phase 2 | 2002-04-01 |
| Completed | Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Ovarian Neoplasms | Phase 2 | 2001-06-01 |
| Completed | Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Non Small Cell Lung Carcinoma | Phase 3 | — |